menu
    • menu
    [{"orgOrder":0,"company":"Eyam Vaccines and Immunotherapeutics","sponsor":"Mitacs","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"CANADA","productType":"Vaccine","year":"2022","type":"Partnership","leadProduct":"Self-Amplifying Mrna Vaccine","moa":"SARS-CoV-2 S","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Eyam Vaccines and Immunotherapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Eyam Vaccines and Immunotherapeutics \/ Mitacs","highestDevelopmentStatusID":"4","companyTruncated":"Eyam Vaccines and Immunotherapeutics \/ Mitacs"}]

    Find Clinical Drug Pipeline Developments & Deals by Eyam Vaccines and Immunotherapeutics

    Menu

    Eyam Vaccines and Immunotherapeutics

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Eyam Vaccines and Immunotherapeutics

                            Canada arrow
                            IMCAS Asia
                            Not Confirmed

                            Eyam Vaccines and Immunotherapeutics

                            Canada arrow
                            IMCAS Asia
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Self-Amplifying Mrna Vaccine

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Preclinical

                            Sponsor : Mitacs

                            Deal Size : Undisclosed

                            Deal Type : Partnership

                            DEALS_DEV arrow-down

                            Eyam Announces Partnership with Mitacs to Fund Next Generation COVID-19 Vaccine Technologies

                            Details : Through this program, Mitacs, will help fund the collaborative work that Eyam and UBC are advancing, supporting significant research efforts that could profoundly impact the future of vaccine development (self-amplifying mRNA vaccine) and therapeutics.

                            Product Name : Undisclosed

                            Product Type : Vaccine

                            Upfront Cash : Undisclosed

                            November 10, 2022

                            Lead Product(s) : Self-Amplifying Mrna Vaccine

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Preclinical

                            Sponsor : Mitacs

                            Deal Size : Undisclosed

                            Deal Type : Partnership

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth